Peplin Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Emeryville CA United States (1998)
Status: Acquired by Leo Pharma (2009)

Organization Overview

First Clinical Trial
2005
NCT00107965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Peplin Operations | Peplin Operations Pty Ltd | Peplin Operations (Sponsor)

Active Ingredients

Drugs in Phase 3 Trials (1)

ingenol mebutate (picato) (26 trials)

Drugs in Phase 2 Trials (2)

Key: Peplin (1) Acquired (1)

aluminum (1 trial)

neosh101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Carcinoma in Situ (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Keratosis, Seborrheic (Phase 2)

Warts (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial APIs: 3